Navigation Links
Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter
Date:2/9/2010

SAN DIEGO, Feb. 9 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the Eagle Eye® Platinum digital IVUS catheter in the United States. This state-of-the-art catheter offers all of the benefits of the predecessor Eagle Eye® Gold catheter, plus improved deliverability and the convenience of additional radiopaque markers. Commercial release of Eagle Eye® Platinum in the U.S. is expected in the second quarter of 2010.

"Multiple studies have shown the benefits of IVUS imaging," commented Scott Huennekens, President and Chief Executive Officer of Volcano. "With Eagle Eye® Platinum, we're now providing clinicians further improvements to our industry-leading catheter design. Despite the fact that our customers have made Eagle Eye® Gold the #1 selling IVUS catheter in the United States, we recognize the need to continuously improve our products to support the treatment of the increasingly challenging blockages or lesions interventional cardiologists are addressing. Our investments in advanced catheter design have resulted in the Eagle Eye® Platinum, a product that has enhanced deliverability, is significantly easier to use, and includes Volcano's proprietary VH® IVUS tissue characterization technology, a unique imaging modality that is backed by 15 years of research and data published in over 100 articles, and has been studied in over 10,000 patients."

Vince Burgess, Group President for Advanced Imaging Systems, remarked, "Clinical data continues to illustrate that angiography alone is often not enough to properly assess and treat coronary lesions. The STLLR (The Impact of Stent Deployment Techniques on Clinical Outcomes on Patients Treated with the Cypher™ Stent) trial was a double-blinded clinical study that showed that geographic miss, which means improperly covering the length of a lesion or vessel blockage, is a contributing factor to poor stenting outcomes, stent thrombosis, and an increased risk of clinical events. In STLLR, where interventions were guided by angiography alone, optimal placement of the stent was achieved in only about half of the procedures. The addition of marker bands is also significant. Although IVUS has been the gold standard for objective measurements of lumen size, plaque composition, and stent expansion, many regular IVUS users still do not use IVUS to make lesion length assessments. Eagle Eye® Platinum's radiopaque markers should provide a quick and easy way for physicians to estimate lengths without the need for a separate pullback device. We believe that this new feature along with the deliverability improvements will increase usage among physicians, allowing for more precision and accuracy in treating blood vessel blockages."

The Eagle Eye® Platinum is the third generation of catheters in the Eagle Eye® product line.  To date, Eagle Eye® catheters have been used in over 500,000 procedures worldwide. Like Eagle Eye® Gold, the Eagle Eye® Platinum catheter offers fast, plug-and-play functionality as well as grayscale IVUS, VH® IVUS, and ChromaFlo® imaging modalities.

About Volcano Corporation

Volcano Corporation offers a broad suite of devices designed to facilitate endovascular procedures, enhance the diagnosis of vascular and structural heart disease and guide optimal therapies. The company's intravascular ultrasound (IVUS) product line includes ultrasound consoles that can be integrated directly into virtually any modern cath lab. Volcano IVUS offers unique features, including both single-use digital and rotational IVUS imaging catheters, and advanced functionality options, such as VH® IVUS tissue characterization and ChromaFlo®. Volcano also provides functional measurement (FM) consoles and single-use pressure and flow guide wires and is developing a line of ultra-high resolution Optical Coherence Tomography (OCT) systems and catheters. Currently, more than 4,700 Volcano IVUS and FM systems are installed worldwide, and more than half of Volcano's revenues are derived from outside the United States. Volcano's wholly-owned subsidiary, Axsun Technologies, develops and manufactures optical monitors, lasers and optical engines used in telecommunications, medical imaging, spectroscopy and other industrial applications. For more information, visit the company's website at www.volcanocorp.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release regarding Volcano's business that are not historical facts may be considered "forward-looking statements," including statements regarding the potential benefits of the products and procedures described above, results and implications of the data from the STLLR trial, commercial release and market adoption of the company's technology, and the impact of clinical and other technical data. Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause Volcano's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from the results predicted are detailed in the company's annual report on Form 10-K, quarterly reports on Form 10-Q and other filings made with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made. Volcano undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

SOURCE Volcano Corporation

RELATED LINKS
http://www.volcanocorp.com

'/>"/>

SOURCE Volcano Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Volcano Corporation Completes Acquisition of Lumen Biomedicals Xtract(TM) Thrombus Aspiration Catheter
2. Volcano Corporation Announces Litigation Status
3. Volcano Corporation Announces Preliminary Record Revenues for Fourth Quarter 2009; Total Year Revenues are Expected to Exceed Prior Guidance
4. Volcano Corporation Commends the Elevation of FFR to Level of Evidence A in New PCI Guidelines
5. Volcano Announces Installed Base Growth Milestone
6. Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging
7. Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast
8. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
9. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
10. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
11. Volcano Sponsors First Study Designed to Determine if IVUS Can Identify Patients at Risk for Stent Thrombosis and to Demonstrate the Benefit of IVUS Guidance for Procedural Outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... OCEANSIDE, Calif. , Aug. 15, 2017  AOTI Inc. announced ... Advanced Oxygen Therapy Inc., has recently opened a New York City ... the ever-increasing usage of its unique Topical Wound Oxygen (TWO 2 ... approved by the Accreditation Commission for Health Care (ACHC) under the ... ...
(Date:8/11/2017)... DarioHealth Corp. (NASDAQ: DRIO), a leading global ... solutions, today announced that it will release its second ... a conference call at 9:00am ET. The Company will ... and its strategy and outlook for the remainder of ... Raphael , Chief Executive Officer, and Zvi Ben-David ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
Breaking Medicine Technology:
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... More than ... Democratic Republic of Congo (DRC) thanks to an ambitious venture that conjoined the passions ... as the generous support of the Liberty community. These shoes will save lives from ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... highly specialized asset-light logistics provider of complex transport solutions for mission-critical and ... purchase Unitrans International Corporation, a division of Roadrunner Transportation Systems, Inc. (NYSE: ...
(Date:8/18/2017)... York, NY (PRWEB) , ... August 18, 2017 ... ... launch of this summer’s edition of “Vision & Hearing,” advocating for active, healthy ... campaign focuses on resources available for individuals with hearing impairments and shares the ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... handling handheld devices. Through an educational webinar, they will present the line of ... chance to learn how easy you can automate everyday pipetting tasks. , Ideal ...
(Date:8/18/2017)... ... August 18, 2017 , ... Hernandez Insurance Agencies, a ... throughout the greater DC region, is inaugurating a “New Leash On Life” charity ... and training them to be companions for veterans in need. , The Semper ...
Breaking Medicine News(10 mins):